{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:31:07Z","timestamp":1792855867096,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The purpose of this study was to investigate choroidal morphology remodeling in AMD-associated type 1 macular neovascularization using two different anti-VEGF drugs. We registered 73 treatment-na\u00efve eyes with a diagnosis of exudative AMD and type 1 MNV. Patients received 3 monthly intravitreal aflibercept (n\u2009=\u200936, aflibercept group [AG]) or brolucizumab (n\u2009=\u200937, brolucizumab group [BG]). Baseline best-corrected visual acuity (BCVA) and anatomical (structural optical coherence tomography) parameters were collected at \u201cT1 control\u201d, before the loading phase (LP) of intravitreal injection, and at \u201cT2 control\u201d, 1\u00a0month after the last injection. The main outcomes measured were choroidal vascularity index (CVI), sub-foveal choroidal thickness (SFCT), and central macular thickness (CMT). Our results displayed significant SFCT reduction in both groups between T1 and T2 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05), We did not find choroidal vascularity modifications (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05) after the loading aflibercept injections. Moreover, only the BG displayed a significant choroidal remodeling (stromal choroidal area [SCA], total choroidal area [TCA] and CVI) at T2 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). In particular, a relevant stromal and total choroidal volume reduction was noted, accompanied by an increase in CVI. To conclude, the latter modifications of the choroidal morphology were found significant between two groups (p\u2009&lt;\u20090.05). Our analysis showed a significant impact of brolucizumab on choroidal morphology in eyes affected by type 1 nAMD. This effect was found relevant when compared with aflibercept.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-52315-w","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T18:09:11Z","timestamp":1705946951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Choroidal remodeling following different anti-VEGF therapies in neovascular AMD"],"prefix":"10.1038","volume":"14","author":[{"given":"Giacomo","family":"Boscia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Pozharitskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Oliva","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u2019Addario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"52315_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.122.4.564","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman, D. S. et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564\u2013572 (2004).","journal-title":"Arch. Ophthalmol."},{"key":"52315_CR2","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0161-6420(93)31466-1","volume":"100","author":"WR Green","year":"1993","unstructured":"Green, W. R. & Enger, C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology 100, 1519\u20131535 (1993).","journal-title":"Ophthalmology"},{"key":"52315_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide, R. F. et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127, 616\u2013636 (2020).","journal-title":"Ophthalmology"},{"key":"52315_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/phar.1264","volume":"33","author":"LK Cheung","year":"2013","unstructured":"Cheung, L. K. & Eaton, A. Age-related macular degeneration. Pharmacotherapy 33, 838\u2013855 (2013).","journal-title":"Pharmacotherapy"},{"key":"52315_CR5","first-page":"74","volume":"59","author":"A Gheorghe","year":"2015","unstructured":"Gheorghe, A., Mahdi, L. & Musat, O. Age-related macular degeneration. Rom. J. Ophthalmol. 59, 74\u201377 (2015).","journal-title":"Rom. J. Ophthalmol."},{"key":"52315_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0002-9394(01)01237-5","volume":"133","author":"NM Bressler","year":"2002","unstructured":"Bressler, N. M. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization\u2014Verteporfin in photodynamic therapy report 2 [4]. Am. J. Ophthalmol. 133, 168\u2013169 (2002).","journal-title":"Am. J. Ophthalmol."},{"key":"52315_CR7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/archopht.1993.01090090052019","volume":"111","author":"Laser Photocoagulation","year":"1993","unstructured":"Laser Photocoagulation. Lesions of age-related macular degeneration. Arch. Ophthalmol. 111, 1200\u20131209 (1993).","journal-title":"Arch. Ophthalmol."},{"key":"52315_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419\u20131431 (2006).","journal-title":"N. Engl. J. Med."},{"key":"52315_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel, P. U. et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127, 72\u201384 (2020).","journal-title":"Ophthalmology"},{"key":"52315_CR10","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani, A. M. et al. TENAYA and LUCERNE: Rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol. Sci. 1, 100076 (2021).","journal-title":"Ophthalmol. Sci."},{"key":"52315_CR11","doi-asserted-by":"publisher","first-page":"c2459","DOI":"10.1136\/bmj.c2459","volume":"340","author":"A Tufail","year":"2010","unstructured":"Tufail, A. et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): Multicentre randomised double masked study. BMJ 340, c2459 (2010).","journal-title":"BMJ"},{"key":"52315_CR12","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537\u20132548 (2012).","journal-title":"Ophthalmology"},{"key":"52315_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","volume":"123","author":"FG Holz","year":"2016","unstructured":"Holz, F. G. et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: A randomized controlled study. Ophthalmology 123, 1080\u20131089 (2016).","journal-title":"Ophthalmology"},{"key":"52315_CR14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki, T., Koizumi, H., Yamagishi, T. & Kinoshita, S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119, 1621\u20131627 (2012).","journal-title":"Ophthalmology"},{"key":"52315_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi, H. et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: Twelve-month results. Ophthalmology 123, 617\u2013624 (2016).","journal-title":"Ophthalmology"},{"key":"52315_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/S00417-021-05517-1","author":"T Tamashiro","year":"2022","unstructured":"Tamashiro, T. et al. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: A short-term multicenter study. Graefes Arch. Clin. Exp. Ophthalmol. https:\/\/doi.org\/10.1007\/S00417-021-05517-1 (2022).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"52315_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10384-022-00908-1","volume":"66","author":"H Ota","year":"2022","unstructured":"Ota, H. et al. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration. Jpn. J. Ophthalmol. 66, 278\u2013284 (2022).","journal-title":"Jpn. J. Ophthalmol."},{"key":"52315_CR18","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/biomedicines9091164","volume":"9","author":"Y Fukuda","year":"2021","unstructured":"Fukuda, Y. et al. Comparison of outcomes between 3 monthly Brolucizumab and Aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines 9, 1164 (2021).","journal-title":"Biomedicines"},{"key":"52315_CR19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","volume":"128","author":"J Mon\u00e9s","year":"2021","unstructured":"Mon\u00e9s, J. et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: Post hoc review of HAWK and HARRIER. Ophthalmology 128, 1050\u20131059 (2021).","journal-title":"Ophthalmology"},{"key":"52315_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00417-020-04620-z","volume":"258","author":"K Lee","year":"2020","unstructured":"Lee, K., Park, J. H., Park, Y. G. & Park, Y. H. Analysis of choroidal thickness and vascularity in patients with unilateral polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 258, 1157\u20131164 (2020).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"52315_CR21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ajo.2013.07.001","volume":"156","author":"HJ Cho","year":"2013","unstructured":"Cho, H. J. et al. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 156, 1192 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"52315_CR22","doi-asserted-by":"publisher","first-page":"102582","DOI":"10.1016\/j.pdpdt.2021.102582","volume":"36","author":"A Alis","year":"2021","unstructured":"Alis, A. & Guler Alis, M. Long-term effect of intravitreal aflibercept treatment on choroidal vascularity index in neovascular age-related macular degeneration. Photodiagn. Photodyn. Ther. 36, 102582 (2021).","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"52315_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm11195517","volume":"11","author":"P Viggiano","year":"2022","unstructured":"Viggiano, P. et al. Short-term morphofunctional changes in previously treated neovascular AMD eyes switched to brolucizumab. J. Clin. Med. 11, 1 (2022).","journal-title":"J. Clin. Med."},{"key":"52315_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12886-022-02711-5","volume":"22","author":"SW Nam","year":"2022","unstructured":"Nam, S. W., Byun, Z., Ham, D. & Kong, M. Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy. BMC Ophthalmol. 22, 5 (2022).","journal-title":"BMC Ophthalmol."},{"key":"52315_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies, M. C. et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: A randomized clinical trial. JAMA Ophthalmol. 137, 372\u2013379 (2019).","journal-title":"JAMA Ophthalmol."},{"key":"52315_CR26","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","volume":"124","author":"PU Dugel","year":"2017","unstructured":"Dugel, P. U. et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: A randomized trial. Ophthalmology 124, 1296\u20131304 (2017).","journal-title":"Ophthalmology"},{"key":"52315_CR27","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.ophtha.2008.08.016","volume":"115","author":"PA Keane","year":"2008","unstructured":"Keane, P. A. et al. Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology 115, 2206\u20132214 (2008).","journal-title":"Ophthalmology"},{"key":"52315_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep21090","volume":"6","author":"R Agrawal","year":"2016","unstructured":"Agrawal, R. et al. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. Sci. Rep. 6, 1\u20139 (2016).","journal-title":"Sci. Rep."},{"issue":"Pt 3","key":"52315_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.compmedimag.2015.09.008","volume":"46","author":"KK Vupparaboina","year":"2015","unstructured":"Vupparaboina, K. K., Nizampatnam, S., Chhablani, J., Richhariya, A. & Jana, S. Automated estimation of choroidal thickness distribution and volume based on OCT images of posterior visual section. Comput. Med. Imaging Graph. 46(Pt 3), 315\u2013327 (2015).","journal-title":"Comput. Med. Imaging Graph."},{"key":"52315_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41433-021-01889-0","volume":"37","author":"R Sacconi","year":"2023","unstructured":"Sacconi, R. et al. Choroidal vascularity index in leptochoroid: A comparative analysis between reticular pseudodrusen and high myopia. Eye 37, 75\u201381 (2023).","journal-title":"Eye"},{"key":"52315_CR31","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1167\/iovs.11-8836","volume":"53","author":"T Yamashita","year":"2012","unstructured":"Yamashita, T. et al. Repeatability and reproducibility of subfoveal choroidal thickness in normal eyes of Japanese using different SD-OCT devices. Investig. Ophthalmol. Vis. Sci. 53, 1102\u20131107 (2012).","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52315-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52315-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52315-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T13:06:23Z","timestamp":1706274383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52315-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52315"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52315-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"25 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1941"}}